A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer.

Trial Profile

A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2012 Additional lead trial centre (National Institutes of Health Clinical Center) identified as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Additional lead trial centre (National Institutes of Health Clinical Center) identified as reported by ClinicalTrials.gov.
    • 11 Jan 2009 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top